We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer.
- Authors
Pao, William; Chmielecki, Juliann
- Abstract
Epidermal growth factor receptor (EGFR)-mutant non-small-cell lung cancer (NSCLC) was first recognized in 2004 as a distinct, clinically relevant molecular subset of lung cancer. The disease has been the subject of intensive research at both the basic scientific and clinical levels, becoming a paradigm for how to understand and treat oncogene-driven carcinomas. Although patients with EGFR-mutant tumours have increased sensitivity to tyrosine kinase inhibitors (TKIs), primary and acquired resistance to these agents remains a major clinical problem. This Review summarizes recent developments aimed at treating and ultimately curing the disease.
- Subjects
EPIDERMAL growth factor; SMALL cell lung cancer; CANCER genes; ONCOGENES; PROTEIN-tyrosine kinases; ANTINEOPLASTIC agents; PROTEIN kinase inhibitors; DRUG resistance in cancer cells; LUNG cancer; LUNG tumors; GENETIC mutation; RESEARCH funding; CHEMICAL inhibitors; THERAPEUTICS
- Publication
Nature Reviews Cancer, 2010, Vol 10, Issue 11, p760
- ISSN
1474-175X
- Publication type
journal article
- DOI
10.1038/nrc2947